Terms: = Lymphoma AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH
302 results:
1. Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular lymphoma.
Kahl BS; Jegede OA; Peterson C; Swinnen LJ; Habermann TM; Schuster SJ; Weiss M; Fishkin PA; Fenske TS; Williams ME
J Clin Oncol; 2024 Mar; 42(7):774-778. PubMed ID: 38194625
[No Abstract] [Full Text] [Related]
2. The association of environmental factors with neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia (ALL).
Nigro SE; Hall LP; Harman J; Willard VW; Conklin HM; Pui CH; Jeha S; Jacola LM
Support Care Cancer; 2023 Dec; 32(1):1. PubMed ID: 38047975
[TBL] [Abstract] [Full Text] [Related]
3. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract] [Full Text] [Related]
4. Serum Albumin Affects the Time-to-treatment Failure of Alectinib: A Multicenter Retrospective Study.
Umehara K; Yama K; Goto K; Hoshi T; Hatakeyama T; Isaji M; Takada S; Yamagishi K; Mino K; Sato H
In Vivo; 2023; 37(5):2260-2267. PubMed ID: 37652488
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of anti-apoptotic protein (Bcl-xl) levels and mRNA expression in infertile patients.
Hashem R; Al-Obaidi ZF; Samawi FT; Baher H
Afr J Reprod Health; 2022 Oct; 26(10):63-71. PubMed ID: 37585047
[TBL] [Abstract] [Full Text] [Related]
6. Mitochondrial DNA Fragmentation and Risk of Non-Hodgkin lymphoma.
Hosgood HD; Davitt M; Cawthon R; Weinstein SJ; Blechter B; Wong JYY; Rahman ML; Hu W; Männistö S; Albanes D; Rothman N; Lan Q
JAMA Netw Open; 2023 Aug; 6(8):e2326885. PubMed ID: 37531109
[TBL] [Abstract] [Full Text] [Related]
7. Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
Muffly L; Young C; Feng Q; Nimke D; Pandya BJ
Leuk Lymphoma; 2023; 64(11):1832-1839. PubMed ID: 37486091
[TBL] [Abstract] [Full Text] [Related]
8. Undifferentiated component of dedifferentiated endometrial carcinoma presenting as a "small round cell" malignancy in a mediastinal lymph node, mimicking small cell carcinoma.
Balikani L; Policarpio-Nicolas MLC
Diagn Cytopathol; 2023 Aug; 51(8):519-524. PubMed ID: 37318779
[TBL] [Abstract] [Full Text] [Related]
9. [Association of Geriatric Nutritional Risk Index with Adverse Events and Time to Treatment Failure in Malignant lymphoma Patients Treated with(R-)EPOCH].
Kikuchi K; Yama K; Misaka H; Takeda G; Watanabe T; Souma T; Harada T; Lang L; Yamawaki F; Saga T; Ishihara T; Sato H
Gan To Kagaku Ryoho; 2023 Jun; 50(6):701-705. PubMed ID: 37317604
[TBL] [Abstract] [Full Text] [Related]
10. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
Liang EC; Dekker SE; Sabile JMG; Torelli S; Zhang A; Miller K; Shiraz P; Hayes-Lattin B; Leonard JT; Muffly L
Blood Adv; 2023 Jul; 7(14):3395-3402. PubMed ID: 37196642
[TBL] [Abstract] [Full Text] [Related]
11. Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
Correia C; Maurer MJ; McDonough SJ; Schneider PA; Ross PE; Novak AJ; Feldman AL; Cerhan JR; Slager SL; Witzig TE; Eckloff BW; Li H; Nowakowski GS; Kaufmann SH
Blood Cancer J; 2023 May; 13(1):81. PubMed ID: 37193683
[TBL] [Abstract] [Full Text] [Related]
12. Influence of Geriatric Nutritional Risk Index on Occurrence of Adverse Events and Duration of Treatment in Patients With lymphoma Receiving R-CHOP Therapy.
Kikuchi K; Sawada M; Takeda G; Watanabe T; Souma T; Sato H
In Vivo; 2023; 37(3):1297-1303. PubMed ID: 37103079
[TBL] [Abstract] [Full Text] [Related]
13. A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma.
Wang T; Du G; Niu M; Liu R
BMC Pulm Med; 2023 Feb; 23(1):60. PubMed ID: 36755262
[TBL] [Abstract] [Full Text] [Related]
14. Performance of the HAS-BLED, ORBIT, and ATRIA Bleeding Risk Scores on a Cohort of 399 344 Hospitalized Patients With Atrial Fibrillation and Cancer: Data From the French National Hospital Discharge Database.
Pastori D; Marang A; Bisson A; Herbert J; Lip GYH; Fauchier L
J Am Heart Assoc; 2022 Dec; 11(23):e026388. PubMed ID: 36444864
[TBL] [Abstract] [Full Text] [Related]
15. Association of antibiotic-consumption patterns with the prevalence of hematological malignancies in European countries.
Ternák G; Berényi K; Németh B; Szenczi Á; Márovics G; Kiss I
Sci Rep; 2022 May; 12(1):7821. PubMed ID: 35550556
[TBL] [Abstract] [Full Text] [Related]
16. Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method.
Bommier C; Lambert J; Nowakowski G; Zucca E; Thieblemont C
Hematol Oncol; 2022 Dec; 40(5):1086-1089. PubMed ID: 35299287
[TBL] [Abstract] [Full Text] [Related]
17. Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.
Dourthe ME; Phulpin A; Auperin A; Bosq J; Couec ML; Dartigues P; Ducassou S; Garnier N; Haouy S; Leblanc T; Leruste A; Paillard C; Rigaud C; Simonin M; Patte C; Minard-Colin V
Haematologica; 2022 Sep; 107(9):2173-2182. PubMed ID: 35236054
[TBL] [Abstract] [Full Text] [Related]
18. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
[TBL] [Abstract] [Full Text] [Related]
19. Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
Zou Z; Hao X; Zhang C; Li H; Dong G; Peng Y; Ma K; Guo Y; Shan L; Zhang Y; Liang L; Gu Y; Xing P; Li J
Thorac Cancer; 2022 Jan; 13(1):107-116. PubMed ID: 34851035
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.
Wang CC; Huang KT; Chang HC; Tseng CC; Lai CH; Lan J; Liu TT; Huang CC; Lin MC
Thorac Cancer; 2022 Jan; 13(1):38-47. PubMed ID: 34841687
[TBL] [Abstract] [Full Text] [Related]
[Next]
